Stealth’s Elamipretide Efficacy In Barth Syndrome Not Shown, US FDA Says

The Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.